The Role of Vitamin D in Parkinson's Disease
DOI:
https://doi.org/10.56479/ijgr-47Keywords:
Vitamin D, Medical nutrition therapy, Parkinson's diseaseAbstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by tremor, rigidity, bradykinesia, and postural instability, along with non-motor symptoms that can cause disability. Vitamin D, a fat-soluble secosteroid, influences gene expression by binding to the vitamin D receptor (VDR). It is essential for calcium homeostasis and metabolism and is also linked to various health conditions, including PD. In recent years, a high prevalence of vitamin D deficiency has been observed in PD patients. The enzymes converting vitamin D to its active form, VDR, and 1α-hydroxylase, are highly expressed in the substantia nigra. These findings indicate that low vitamin D levels may cause dysfunction or cell death in this brain region. Vitamin D impacts several biological processes in the central nervous system, including neurotransmission in dopaminergic circuits. Studies show lower vitamin D levels in Parkinson's patients compared to healthy controls. Links have been found between vitamin D levels and non-motor symptoms like mood disorders, orthostatic hypotension, and olfactory dysfunction, as well as motor severity. However, information on vitamin D's effects on non-motor symptoms is limited. This review seeks to critically examine the relationship between vitamin D and PD, focusing on the potential mechanisms through which vitamin D may influence the development, progression, and clinical management of PD. Additionally, it aims to evaluate the role of vitamin D in the prevention of PD and its therapeutic potential as an adjunctive treatment in patients with Parkinson’s disease.
Downloads
References
Allen, M. T., & Levy, L. S. (2013). Parkinson’s disease and pesticide exposure – a new assessment. Critical Reviews Toxicology, 43, 515–34. https://doi.org/10.3109/10408444.2013.798719
AlJohri, R., AlOkail, M., Haq,S.H. (2019). Neuroprotective role of vitamin D in primary neuronal cortical culture. Neurological Science, 14, 43-48. https://doi.org/10.1016/j.ensci.2018.12.004
Amrein, K., Scherkl, M., Hoffmann, M., Neuwersch-Sommeregger, S., Köstenberger, M., Tmava Berisha, A., ... & Malle, O. (2020). Vitamin D deficiency 2.0: An update on the current status worldwide. European Journal of Clinical Nutrition, 74(11), 1498-1513. https://doi.org/10.1038/s41430-020-0558-y
Barichella, M., Garrì, F., Caronni, S., Bolliri, C., Zocchi, L., Macchione, M. C., ... & Pezzoli, G. (2022). Vitamin D status and Parkinson’s disease. Brain Sciences, 12(6), 790. https://doi.org/10.3390/brainsci12060790
Bischoff-Ferrari, H. A., Dawson-Hughes, B., Staehelin, H. B., Orav, J. E., Stuck, A. E., Theiler, R., ... & Henschkowski, J. (2009). Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ, 339. https://doi.org/10.1136/bmj.b3692
Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284-2303. https://doi.org/10.1016/S0140-6736(21)00218-X
Bohnen, N. I., & Albin, R. L. (2011). The cholinergic system and Parkinson disease. Behavioural brain research, 221(2), 564-573. https://doi.org/10.1016/j.bbr.2009.12.048
Bouillon, R. (2018). Extra-skeletal effects of vitamin D. Vitamin D in Clinical Medicine, 50, 72-88. https://doi.org/10.1159/000486072
Burne, T. H., McGrath, J. J., Eyles, D. W., & Mackay-Sim, A. (2005). Behavioural characterization of vitamin D receptor knockout mice. Behavioural Brain Research, 157(2), 299-308. https://doi.org/10.1016/j.bbr.2004.07.008
Butler, M. W., Burt, A., Edwards, T. L., Zuchner, S., Scott, W. K., Martin, E. R., ... & Wang, L. (2011). Vitamin D receptor gene as a candidate gene for Parkinson disease. Annals of Human Genetics, 75(2), 201-210. https://doi.org/10.1111/j.1469-1809.2010.00631.x
Bytowska, Z. K., Korewo-Labelle, D., Berezka, P., Kowalski, K., Przewłócka, K., Libionka, W., Kaczor, J. J. (2023). Effect of 12-week BMI-based vitamin D3 supplementation in Parkinson’s disease with deep brain stimulation on physical performance, inflammation, and vitamin D metabolites. International Journal of Molecular Sciences, 24(12), 10200. https://doi.org/10.3390/ijms241210200
Carthy, E. P., Yamashita, W., Hsu, A., & Ooi, B. S. (1989). 1, 25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension, 13(6_pt_2), 954-959. https://doi.org/10.1161/01.HYP.13.6.954
Corti, O., Lesage, S., & Brice, A. (2011). What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiological reviews. 91(4), 1161-1218. https://doi.org/10.1152/physrev.00022.2010
DeLuca, G. C., Li, G., & Ramagopalan, S. (2011). Parkinson disease and vitamin D: an interplay between genes and the environment?. Archives of neurology, 68(12), 1615-1616. https://doi.org/10.1001/archneurol.2011.1078
Ding, H., Dhima, K., Lockhart, K. C., Locascio, J. J., Hoesing, A. N., Duong, K., ... & Scherzer, C. R. (2013). Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology, 81(17), 1531-1537. https://doi.org/10.1212/WNL.0b013e3182a95818
Di Somma, C., Scarano, E., Barrea, L., Zhukouskaya, V. V., Savastano, S., Mele, C., ... & Marzullo, P. (2017). Vitamin D and neurological diseases: an endocrine view. International journal of molecular sciences, 18(11), 2482. https://doi.org/10.3390/ijms18112482
Duval, G. T., Brangier, A., Barré, J., Launay, C. P., Beauchet, O., & Annweiler, C. (2015). Vitamin D deficiency and incident onset of orthostatic hypotension in older adults: preliminary results from the'MERE'study. Journal of the American Geriatrics Society, 63(6), 1245-1247.
Eyles, D. W., Smith, S., Kinobe, R., Hewison, M., & McGrath, J. J. (2005). Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. Journal of chemical neuroanatomy, 29(1), 21-30. https://doi.org/10.1016/j.jchemneu.2004.08.006
Evatt, M. L., DeLong, M. R., Khazai, N., Rosen, A., Triche, S., & Tangpricha, V. (2008). Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Archives of neurology, 65(10), 1348-1352. https://doi.org/10.1001/archneur.65.10.1348
Evatt, M. L., DeLong, M. R., Kumari, M., Auinger, P., McDermott, M. P., Tangpricha, V., & Parkinson Study Group DATATOP Investigators. (2011). High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Archives of neurology, 68(3), 314-319. https://doi.org/10.1001/archneurol.2011.30
Fullard, M. E., Xie, S. X., Marek, K., Stern, M., Jennings, D., Siderowf, A., ... & Chen‐Plotkin, A. S. (2017). Vitamin D in the Parkinson associated risk syndrome (PARS) study. Movement Disorders, 32(11), 1636-1640. https://doi.org/10.1002/mds.27127
Fullard, M. E., Duda, J. E. (2020). A review of the relationship between vitamin D and Parkinson disease symptoms. Frontiers in neurology, 11, 529840. https://doi.org/10.3389/fneur.2020.00454
Garcion, E., Wion-Barbot, N., Montero-Menei, C. N., Berger, F., & Wion, D. (2002). New clues about vitamin D functions in the nervous system. Trends in Endocrinology & Metabolism, 13(3), 100-105. https://doi.org/10.1016/S1043-2760(01)00547-1
Gao, H., Wei, X., Liao, J., Wang, R., Xu, J., Liu, X., ... & Wang, Q. (2015). Lower bone mineral density in patients with Parkinson’s disease: a cross-sectional study from Chinese Mainland. Frontiers in aging neuroscience, 7, 203. https://doi.org/10.3389/fnagi.2015.00203
Gao, J., Teng, J., Liu, Z., Cai, M., & Xie, A. (2020). Association between vitamin D receptor polymorphisms and susceptibility to Parkinson's disease: an updated meta-analysis. Neuroscience Letters, 720, 134778. https://doi.org/10.1016/j.neulet.2020.134778
Gatto, N. M., Paul, K. C., Sinsheimer, J. S., Bronstein, J. M., Bordelon, Y., Rausch, R., & Ritz, B. (2016). Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson's disease. Journal of the Neurological Sciences, 370, 100-106. https://doi.org/10.1016/j.jns.2016.09.013
Giovannucci, E., Liu, Y., Hollis, B. W., & Rimm, E. B. (2008). 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Archives of internal medicine, 168(11), 1174-1180. https://doi.org/10.1001/archinte.168.11.1174
Habibi, A. H., Anamoradi, A., Shahidi, G. A., Razmeh, S., Alizadeh, E., & Kokhedan, K. M. (2018). Treatment of Levodopainduced dyskinesia with Vitamin D: A Randomized, double-blind, placebo-controlled trial. Neurology International, 10(3), 7737. https://doi.org/10.4081/ni.2018.7737
Han, X., Xue, L., Li, Y., Chen, B., & Xie, A. (2012). Vitamin D receptor gene polymorphism and its association with Parkinson's disease in Chinese Han population. Neuroscience Letters, 525(1), 29-33. https://doi.org/10.1016/j.neulet.2012.07.033
Hiller, A. L., Murchison, C. F., Lobb, B. M., O’Connor, S., O’Connor, M., & Quinn, J. F. (2018). A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter?. PloS one, 13(9), e0203637. https://doi.org/10.1371/journal.pone.0203637
Hirsch, L., Jette, N., Frolkis, A., Steeves, T., & Pringsheim, T. (2016). The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology, 46(4), 292-300. https://doi.org/10.1159/000445751
Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A., Heaney, R. P., ... & Weaver, C. M. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology & metabolism, 96(7), 1911-1930. https://doi.org/10.1210/jc.2011-0385
Jang, W., Park, J., Kim, J. S., Youn, J., Oh, E., Kwon, K. Y., ... & Kim, H. T. (2015). Vitamin D deficiency in Parkinson's disease patients with orthostatic hypotension. Acta Neurologica Scandinavica, 132(4), 242-250. https://doi.org/10.1111/ane.12390
Jankovic, J., & Tan, E. K. (2020). Parkinson’s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry, 91(8), 795-808. https://doi.org/10.1136/jnnp-2019-322338
Kang, S. Y., Park, S., Oh, E., Park, J., Youn, J., Kim, J. S., ... & Jang, W. (2016). Vitamin D receptor polymorphisms and Parkinson’s disease in a Korean population: revisited. Neuroscience Letters, 628, 230-235. https://doi.org/10.1016/j.neulet.2016.06.041
Kempker, J. A., Tangpricha, V., Ziegler, T. R., & Martin, G. S. (2012). Vitamin D in sepsis: from basic science to clinical impact. Critical Care, 16, 1-6. https://doi.org/10.1186/cc11252
Kenborg, L., Lassen, C. F., Ritz, B., Schernhammer, E. S., Hansen, J., Gatto, N. M., & Olsen, J. H. (2011). Outdoor work and risk for Parkinson's disease: a population-based case–control study. Occupational and environmental medicine, 68(4), 273-278. https://doi.org/10.1136/oem.2010.057448
Kilkkinen, A., Knekt, P., Heliövaara, M., Rissanen, H., Marniemi, J., Hakulinen, T., & Aromaa, A. (2008). Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiology Biomarkers & Prevention, 17(11), 3274-3278. https://doi.org/10.1158/1055-9965.EPI-08-0199
Kim, J. S., Kim, Y. I., Song, C., Yoon, I., Park, J. W., Choi, Y. B., ... & Lee, K. S. (2005). Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. Journal of Korean medical science, 20(3), 495-498. https://doi.org/10.3346/jkms.2005.20.3.495
Kim, J. E., Oh, E., Park, J., Youn, J., Kim, J. S., & Jang, W. (2018). Serum 25-hydroxyvitamin D3 level may be associated with olfactory dysfunction in de novo Parkinson's disease. Journal of Clinical Neuroscience, 57, 131-135. https://doi.org/10.1016/j.jocn.2018.08.003
Knekt, P., Laaksonen, M., Mattila, C., Härkänen, T., Marniemi, J., Heliövaara, M., ... & Reunanen, A. (2008). Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology, 19(5), 666-671. https://doi.org/10.1097/EDE.0b013e318176b8ad
Knekt, P., Kilkkinen, A., Rissanen, H., Marniemi, J., Sääksjärvi, K., & Heliövaara, M. (2010). Serum vitamin D and the risk of Parkinson disease. Archives of neurology, 67(7), 808-811. https://doi.org/10.1001/archneurol.2010.120
Koduah, P., Paul, F., & Dörr, J. M. (2017). Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. Epma Journal, 8(4), 313-325. https://doi.org/10.1007/s13167-017-0120-8
Kravietz, A., Kab, S., Wald, L., Dugravot, A., Singh-Manoux, A., Moisan, F., & Elbaz, A. (2017). Association of UV radiation with Parkinson disease incidence: A nationwide French ecologic study. Environmental research, 154, 50-56. https://doi.org/10.1016/j.envres.2016.12.008
Kwon, E., Gallagher, L. G., Nielsen, S. S., Franklin, G. M., Littell, C. T., Longstreth Jr, W. T., ... & Checkoway, H. (2013). Parkinson's disease and history of outdoor occupation. Parkinsonism & related disorders, 19(12), 1164-1166. https://doi.org/10.1016/j.parkreldis.2013.08.014
Kwon, K. Y., Jo, K. D., Lee, M. K., Oh, M., Kim, E. N., Park, J., ... & Jang, W. (2016). Low serum vitamin D levels may contribute to gastric dysmotility in de novo Parkinson's disease. Neurodegenerative Diseases, 16(3-4), 199-205. https://doi.org/10.1159/000441917
Landel, V., Stephan, D., Cui, X., Eyles, D., & Feron, F. (2018). Differential expression of vitamin D-associated enzymes and receptors in brain cell subtypes. The Journal of steroid biochemistry and molecular biology, 177, 129-134. https://doi.org/10.1016/j.jsbmb.2017.09.008
Lang, Y., Gong, D., & Fan, Y. (2015). Calcium channel blocker use and risk of Parkinson's disease: a meta‐analysis. Pharmacoepidemiology and drug safety, 24(6), 559-566. https://doi.org/10.1002/pds.3781
Langa, F., & Leibrockc, K. M. C. B. (2019). Brain function and neuropsychiatric disease. Neurosignals, 27, 40-49. https://doi.org/10.33594/000000182
Lang, F., Ma, K., Leibrock, C. B., Salker, M. S., & Singh, Y. (2020). The Putative Role of 1, 25 (OH) 2 D 3 in the Association of Milk Consumption and Parkinson's Disease. Neuro-signals, 28(1), 14-24. https://doi.org/10.33594/000000321
Liang, Q., Cai, C., Duan, D., Hu, X., Hua, W., Jiang, P., ... & Gao, Z. (2018). Postnatal vitamin D intake modulates hippocampal learning and memory in adult mice. Frontiers in neuroscience, 12, 141. https://doi.org/10.3389/fnins.2018.00141
Llewellyn, D. J., Lang, I. A., Langa, K. M., Muniz-Terrera, G., Phillips, C. L., Cherubini, A., ... & Melzer, D. (2010). Vitamin D and risk of cognitive decline in elderly persons. Archives of internal medicine, 170(13), 1135-1141.
Littlejohns, T. J., Henley, W. E., Lang, I. A., Annweiler, C., Beauchet, O., Chaves, P. H., ... & Llewellyn, D. J. (2014). Vitamin D and the risk of dementia and Alzheimer disease. Neurology, 83(10), 920-928. https://doi.org/10.1212/WNL.0000000000000755
Lv, L., Tan, X., Peng, X., Bai, R., Xiao, Q., Zou, T., Wang, C. (2020). The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson’s disease. Translational neurodegeneration, 9, 1-13. https://doi.org/10.1186/s40035-020-00213-2
Lubomski, M., Davis, R. L., & Sue, C. M. (2020). Gastrointestinal dysfunction in Parkinson’s disease. Journal of neurology, 267, 1377-1388. https://doi.org/10.1007/s00415-020-09723-5
Metta, V., Sanchez, T. C., & Padmakumar, C. (2017). Osteoporosis: a hidden nonmotor face of Parkinson's disease. International review of neurobiology, 134, 877-890. https://doi.org/10.1016/bs.irn.2017.05.034
McCullough, P. J., Lehrer, D. S., & Amend, J. (2019). Daily oral dosing of vitamin D3 using 5000 TO 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience. The Journal of steroid biochemistry and molecular biology, 189, 228-239. https://doi.org/10.1016/j.jsbmb.2018.12.010
Moghaddasi, M., Mamarabadi, M., & Aghaii, M. (2013). Serum 25-hydroxyvitamin D3 concentration in Iranian patients with Parkinson's disease. Iranian journal of neurology, 12(2), 56.
Newmark, H. L., & Newmark, J. (2007). Vitamin D and Parkinson's disease—a hypothesis. Movement disorders, 22(4), 461-468. https://doi.org/10.1002/mds.21317
Ometto, F., Stubbs, B., Annweiler, C., Duval, G. T., Jang, W., Kim, H. T., ... & Veronese, N. (2016). Hypovitaminosis D and orthostatic hypotension: a systematic review and meta-analysis. Journal of hypertension, 34(6), 1036-1043. https://doi.org/10.1097/HJH.0000000000000907
Park, S. B., Chung, C. K., Lee, J. Y., Lee, J. Y., & Kim, J. (2019). Risk factors for vertebral, hip, and femoral fractures among patients with Parkinson's disease: A 5-year follow-up in Korea. Journal of the American Medical Directors Association, 20(5), 617-623. https://doi.org/10.1016/j.jamda.2018.08.014
Pertile, R. A., Cui, X., & Eyles, D. W. (2016). Vitamin D signaling and the differentiation of developing dopamine systems. Neuroscience, 333, 193-203. https://doi.org/10.1016/j.neuroscience.2016.07.020
Peterson, A. L., Mancini, M., & Horak, F. B. (2013). The relationship between balance control and vitamin D in Parkinson's disease—a pilot study. Movement Disorders, 28(8), 1133-1137. https://doi.org/10.1002/mds.25405
Pignolo, A., Mastrilli, S., Davì, C., Arnao, V., Aridon, P., dos Santos Mendes, F. A., D’Amelio, M. (2022). Vitamin D and Parkinson’s disease. Nutrients, 14(6), 1220. https://doi.org/10.3390/nu14061220
Plantone, D., Primiano, G., Manco, C., Locci, S., Servidei, S., & De Stefano, N. (2022). Vitamin D in neurological diseases. International Journal of Molecular Sciences, 24(1), 87. https://doi.org/10.3390/ijms24010087
Plum, L. A., & DeLuca, H. F. (2010). Vitamin D, disease and therapeutic opportunities. Nature reviews Drug discovery, 9(12), 941-955. https://doi.org/10.1038/nrd3318
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., ... & Lang, A. E. (2017). Parkinson disease. Nature reviews Disease primers, 3(1), 1-21. https://doi.org/10.1038/nrdp.2017.13
Rcom‐H'cheo‐Gauthier, A. N., Meedeniya, A. C., & Pountney, D. L. (2017). Calcipotriol inhibits α‐synuclein aggregation in SH‐SY 5Y neuroblastoma cells by a Calbindin‐D28k‐dependent mechanism. Journal of Neurochemistry, 141(2), 263-274. https://doi.org/10.1111/jnc.13971
Reid, I. R. (2020). A broader strategy for osteoporosis interventions. Nature Reviews Endocrinology, 16(6), 333-339. https://doi.org/10.1038/s41574-020-0339-7
Rimmelzwaan, L. M., van Schoor, N. M., Lips, P., Berendse, H. W., & Eekhoff, E. M. (2016). Systematic review of the relationship between vitamin D and Parkinson’s disease. Journal of Parkinson's disease, 6(1), 29-37. https://doi.org/10.3233/JPD-150615
Salamon, H., Bruiners, N., Lakehal, K., Shi, L., Ravi, J., Yamaguchi, K. D., ... & Gennaro, M. L. (2014). Cutting edge: vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection. The Journal of Immunology, 193(1), 30-34. https://doi.org/10.4049/jimmunol.1400736
Sanchez, B., Lopez-Martin, E., Segura, C., Labandeira-Garcia, J. L., & Perez-Fernandez, R. (2002). 1, 25-Dihydroxyvitamin D3 increases striatal GDNF mRNA and protein expression in adult rats. Molecular Brain Research, 108(1-2), 143-146. https://doi.org/10.1016/S0169-328X(02)00545-4
Sato, Y., Kikuyama, M., & Oizumi, K. (1997). High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease [RETRACTED]. Neurology, 49(5), 1273-1278. https://doi.org/10.1212/WNL.49.5.1273
Sato, Y., Iwamoto, J., & Honda, Y. (2011). Vitamin D deficiency-induced vertebral fractures may cause stooped posture in Parkinson disease. American Journal of Physical Medicine & Rehabilitation, 90(4), 281-286. https://doi.org/10.1097/PHM.0b013e3182063a42
Scherzer, C. R., Eklund, A. C., Morse, L. J., Liao, Z., Locascio, J. J., Fefer, D., ... & Gullans, S. R. (2007). Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences, 104(3), 955-960. https://doi.org/10.1073/pnas.0610204104
Shrestha, S., Lutsey, P. L., Alonso, A., Huang, X., Mosley Jr, T. H., & Chen, H. (2016). S erum 25‐hydroxyvitamin D concentrations in Mid‐adulthood and P arkinson's disease risk. Movement Disorders, 31(7), 972-978. https://doi.org/10.1002/mds.26573
Shirvani, A., Kalajian, T. A., Song, A., Allen, R., Charoenngam, N., Lewanczuk, R., & Holick, M. F. (2020). Variable genomic and metabolomic responses to varying doses of vitamin D supplementation. Anticancer Research, 40(1), 535-543. https://doi.org/10.21873/anticanres.13982
Sleeman, I., Aspray, T., Lawson, R., Coleman, S., Duncan, G., Khoo, T. K., ... & Yarnall, A. (2017). The role of vitamin D in disease progression in early Parkinson’s disease. Journal of Parkinson's disease, 7(4), 669-675. https://doi.org/10.3233/JPD-171122
Sosa Henríquez, M., & Gómez de Tejada Romero, M. J. (2020). Cholecalciferol or calcifediol in the management of vitamin D deficiency. Nutrients, 12(6), 1617. https://doi.org/10.3390/nu12061617
Suzuki, M., Yoshioka, M., Hashimoto, M., Murakami, M., Kawasaki, K., Noya, M., ... & Urashima, M. (2012). 25‐hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. Movement Disorders, 27(2), 264-271. https://doi.org/10.1002/mds.24016
Suzuki, M., Yoshioka, M., Hashimoto, M., Murakami, M., Noya, M., Takahashi, D., & Urashima, M. (2013). Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. The American journal of clinical nutrition, 97(5), 1004-1013. https://doi.org/10.3945/ajcn.112.051664
Tanaka, K., Miyake, Y., Fukushima, W., Kiyohara, C., Sasaki, S., Tsuboi, Y., ... & Fukuoka Kinki Parkinson’s Disease Study Group. (2017). Vitamin D receptor gene polymorphisms, smoking, and risk of sporadic Parkinson’s disease in Japan. Neuroscience Letters, 643, 97-102. https://doi.org/10.1016/j.neulet.2017.02.037
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021). Challenges in the diagnosis of Parkinson's disease. The Lancet Neurology, 20(5), 385-397. https://doi.org/10.1016/S1474-4422(21)00030-2
Topal, K., Paker, N., Bugdayci, D., Ozer, F., & Tekdos, D. (2010, May). Bone mineral density and vitamin D status with idiopathic Parkinson's disease. In Osteoporosis International (Vol. 21, pp. 141-142). Springer.
Wang, J. Y., Wu, J. N., Cherng, T. L., Hoffer, B. J., Chen, H. H., Borlongan, C. V., & Wang, Y. (2001). Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain research, 904(1), 67-75. https://doi.org/10.1016/S0006-8993(01)02450-7
Wang, L., Evatt, M. L., Maldonado, L. G., Perry, W. R., Ritchie, J. C., Beecham, G. W., ... & Scott, W. K. (2015). Vitamin D from different sources is inversely associated with Parkinson disease. Movement disorders, 30(4), 560-566. https://doi.org/10.1002/mds.26117
Wrzosek, M., Łukaszkiewicz, J., Wrzosek, M., Jakubczyk, A., Matsumoto, H., Piątkiewicz, P., ... & Nowicka, G. (2013). Vitamin D and the central nervous system. Pharmacological reports, 65(2), 271-278. https://doi.org/10.1016/s1734-1140(13)71003-x
Yilmazer, S., Dursun, E., & Gezen-Ak, D. (2013). Vitamin D inquiry in hippocampal neurons: consequences of vitamin D-VDR pathway disruption on calcium channel and the vitamin D requirement. Neurology Science. 34, 1453–1458. https://doi.org/10.1007/s10072-012-1268-6
Zhou, Z., Zhou, R., Zhang, Z., & Li, K. (2019). The association between vitamin D status, vitamin D supplementation, sunlight exposure, and Parkinson’s disease: a systematic review and meta-analysis. Medical science monitor: International medical journal of experimental and clinical research, 25, 666-674. https://doi.org/10.12659/MSM.912840
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Fatma Öznur Afacan, Didem Önay Derin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing (CC BY-NC 4.0): This license allows others to remix, adapt, and build upon the work for non-commercial purposes, provided that appropriate credit is given to IJGR. Authors may also share their complete publications freely, without any restrictions.
The journal is licensed under 